omniture
from common-pcom:html:key:en_segment_includes_overall_segment_header_shtml
PR Newswire: news distribution, targeting and monitoring
Home Page > News Releases > Global

Spring Pharmaceutical Group Inc. Reports Financial Results for the Three and Nine Months Ended December 31, 2018

2019-02-15 05:15

JINING, China, Feb. 15, 2019 /PRNewswire/ -- Spring Pharmaceutical Group, Inc. (OTCQB: CYIG) ("Spring Pharmaceutical" or the "Company") today announced its financial results for the three and nine months ended December 31, 2018.

Three Months Ended December 31, 2018 Financials Highlights

  • Total revenues increased by 13.3% to $19.49 million with growth in sales across all three product categories. Sales of acer truncatum seed oil were particularly strong, increasing by 23.6% to $5.08 million and accounted for 26.1% of total revenues.
  • Overall gross margin increased by 5.8% to 45.2%, as a result of increased contribution from the higher margin acer truncatum seed oil and decreased raw material, packaging and manufacturing costs.
  • Net income attributable to the Company was $4.34 million, or $0.15 per share, compared to $2.78 million, or $0.09 per share, for the same period of the prior fiscal year.

"For the fiscal third quarter ended December 31, 2018, revenues grew by 13.3% (or 18.2% as measured in RMB) to $19.49 million with growth across all three product categories while net income increased by 56.4% to $4.48 million, highlighting continuing momentum in our businesses," commented Mr. Tinghe Yan, Chairman and Chief Executive Officer of the Company.

Mr. Yan continued, "More exciting was that we have started harvesting seed pods from our self-grown acer truncatum bunge tree bases since November 2018, leading to solid increase in both revenues and margin for our acer truncatum seed oil business for the fiscal third quarter. With the rest of the acer truncatum bunge trees at our 5,880 mu planting bases set to become commercially productive one after another in the next two to three years, we are well positioned to further grow and integrate our acer truncatum seed oil business. Looking ahead, we firmly believe that our self-grown planting bases, modern production facilities, strong R&D capabilities, combined with our powerful direct sales model, give us significant competitive advantages in pricing, production and distribution in the long run." 

 Three Months Ended December 31, 2018 Financial Results




For the Three Months Ended December 31,

($ millions, except per share data)


2018


2017


% Change

Revenues


$19.49


$17.21


13.3%

Gross profit


$8.82


$6.79


29.9%

Gross margin


45.2%


39.4%


5.8%

Operating income


$5.93


$3.78


56.8%

Operating margin


30.4%


22.0%


8.4%

Net income attributable to CYIG


$4.34


$2.78


56.4%

Earnings per share


$0.15


$0.09


56.1%

Revenues

For the three months ended December 31, 2018, total revenues increased by $2.28 million, or 13.3%, to $19.49 million from $17.21 million for the same period of the prior fiscal year. The increase in total revenues was across the all three product categories with sales for acer truncatum seed oil was particularly strong. The increase in revenues in RMB was 18.2% which was partially offset by the RMB depreciation versus USD during the three months ended December 31, 2018.

Revenues from health care products increased by $0.55 million, or 8.4%, to $7.16 million for the three months ended December 31, 2018 from $6.60 million for the same period of the prior fiscal year. The actual increase in revenue in RMB was 13.4% as compared to the same period of the prior fiscal year, but 5.0% of the increase was offset by lower USD converted from RMB due to RMB depreciation. The increase in sales of the health care products was primarily due to the expansion of our customer base and the increase in online direct sales. 

Revenues from Huoliyuan capsules increased by $0.76 million, or 11.7%, to $7.25 million for the three months ended December 31, 2018 from $6.49 million for the same period of the prior fiscal year. The actual sales in RMB for the three months ended December 31, 2018 increased by 16.8% compared to the same period of the prior fiscal year but 5.1% of the increase was offset by lower USD converted from RMB due to RMB depreciation. The increase in sales of Huoliyuan capsules was primarily due to the stabilization of market competition.

Revenues from acer truncatum seed oil products increased by $0.97 million, or 23.6%, to $5.08 million for the three months ended December 31, 2018 from $4.11 million for the same period of the prior fiscal year. The actual increase in revenue in RMB was 28.2% as compared to the same period of the prior fiscal year, but 4.6% of the increase was offset by lower USD converted from RMB due to RMB depreciation. The increase in sales of acer truncatum seed oil products was primarily due to the continuing promotions of acer truncatum seed oil at conferences, which highlighted the features and benefits of the product to our distributors and customers. Since July 2015 the Company has produced and sold acer truncatum seed oil extracted from the acer truncatum pods purchased from third party vendors. Approximately 10% of the Company's self-grown acer truncatum trees were harvested for production during the fiscal quarter ended December 31, 2018, and the rest of the self-grown acer truncatum pods will be gradually ready for use in production during the next two to three years depending upon the timing of their harvest.

The sales of health care products, Huoliyuan capsules, and acer truncatum seed oil products accounted for 36.7%, 37.2%, and 26.1%, respectively, of total revenues for the three months ended December 31, 2018, compared to 38.4%, 37.7%, and 23.9%, respectively, for the same period of the prior fiscal year.

The following table summarizes revenues and gross profit by products for the three months ended December 31, 2018 and 2017, respectively:



For the Three Months Ended December 31,



2018


2017



Revenues
($M)


Gross Profit
($M)


Gross Margin
(%)


Revenues
($M)


Gross Profit
($M)


Gross Margin
(%)

Health care supplements


7.16


3.18


44.4%


6.60


2.94


44.5%

Drugs (Huoliyuan capsule)

7.25


2.18


30.1%


6.49


1.99


30.6%

Acer truncatum oil


5.08


3.46


68.1%


4.11


1.87


45.4%

Total


19.49


8.82


45.2%


17.21


6.79


39.4%

Cost of Goods Sold

Cost of goods sold comprised primarily the cost of finished goods purchased from Shandong Yongchuntang, raw materials of our self-grown acer truncatum pods and pods that we purchased from third party vendors, and the manufacturing cost of acer truncatum seed oil products and Huoliyuan capsules. For the three months ended December 31, 2018, total cost of goods sold increased by $0.25 million, or 2.4%, to $10.67 million from $10.42 million for the same period of the prior fiscal year. The actual increase in RMB was 6.8%, but 4.4% of the increase was offset by lower USD converted from RMB due to RMB Depreciation. The increase in total cost of goods sold was due to increased sales and partially offset by decreased production cost of acer truncatum bunge seed oil products due to the using of self-grown acer truncatum pods with cost lower than the pods purchased from third parties.

As a percentage of revenues, total cost of goods sold was 54.8% for the three months ended December 31, 2018, compared to 60.6% for the same period of the prior fiscal year. The decrease in the percentages of the costs of goods sold to total revenues was primarily due to the decreased raw material, packaging and manufacturing cost for acer truncatum bunge seed oil products.

Cost of goods sold for health care products, Huoliyuan capsules, and acer truncatum seed oil products were $3.98 million, $5.07 million and $1.62 million, respectively for the three months ended December 31, 2018, compared to $3.67 million, $4.51 million, and $2.25 million, respectively, for the same period of the prior fiscal year.

Gross Profit

Gross profit increased by $2.03 million, or 29.9%, to $8.82 million for the three months ended December 31, 2018 from $6.79 million for the same period of the prior fiscal year. Gross profit for health care products, Huoliyuan capsules, and acer truncatum seed oil products were $3.18 million, $2.18 million, and $3.46 million, respectively, for the three months ended December 31, 2018, compared to $2.94 million, $1.99 million, and $1.87 million, respectively, for the same period of the prior fiscal year.

Overall gross margin was 45.2%, with gross margins for health care products, Huoliyuan capsules, and acer truncatum seed oil products being 44.4%, 30.1%, and 68.1%, respectively, for the three months ended December 31, 2018. Overall gross margin was 39.4%, and gross margins for health care products, Huoliyuan capsules, and acer truncatum seed oil products were 44.5%, 30.6%, and 45.4%, respectively, for the same period of the prior fiscal year. The increase in overall gross margin was mainly due to the increased contribution from the higher margin acer truncatum seed oil products.

Operating Expenses

Selling expenses consist primarily of sales commissions, advertising and promotion, freight charges, and related compensation. For the three months ended December 31, 2018, selling expenses was essentially unchanged at $1.28 million.

General and administrative expenses decreased by $0.13 million, or 9.2%, to $1.31 million for the three months ended December 31, 2018 from $1.45 million for the same period of the prior fiscal year. The decrease in general and administrative expenses was primarily due to the decrease in legal fees and social security payments offsetting by the increase in consulting fees. 

Research and development expenses were $0.30 million for the three months ended December 31, 2018, compared to $0.28 million for the same period of the prior fiscal year. Our long-term goal is to utilize advanced biological technology to refine and extract the beneficial compounds in plants that have traditionally been known to have medicinal benefits, primarily gingko and acer truncatum bunge plants. As of December 31, 2018, the Company had a staff of 27 in its R&D department.

As a result of the foregoing, total operating expenses decreased by $0.12 million, or 3.9%, to $2.89 million for the three months ended December 31, 2018, from $3.00 million for the same period of the prior fiscal year.

Operating Income

Total operating income increased by $2.15 million, or 56.8%, to $5.93 million for the three months ended December 31, 2018, from $3.78 million for the same period of the prior fiscal year. The increase in total operating income was mainly a result of increased gross profit as well as decreased operating expenses. Operating margin was 30.4% for the three months ended December 31, 2018, compared to 22.0% for the same period of the prior fiscal year.

Income before Income Taxes

Interest income was $35,141 for the three months ended December 31, 2018, compared to $32,376 for the same period of the prior fiscal year.

Income before income tax provisions increased by $2.15 million, or 56.4%, to $5.97 million for the three months ended December 31, 2018, from $3.82 million for the same period of the prior fiscal year.

Net Income

Provision for income tax increased by $0.54 million, or 56.4%, to $1.49 million for the three months ended December 31, 2018, from $0.95 million for the same period of the prior fiscal year.

Net income increased by $1.61 million, or 56.4%, to $4.48 million for the three months ended December 31, 2018, from $2.86 million for the same period of the prior fiscal year.

After the deduction of non-controlling interest, net income attributable to the Company was $4.34 million, or $0.15 per basic and diluted share for the three months ended December 31, 2018, compared to $2.78 million, or $0.09 per basic and diluted share, for the same period of the prior fiscal year.

Nine Months Ended December 31, 2018 Financial Results




For the Nine Months Ended December 31,

($ millions, except per share data)


2018


2017


% Change

Revenues


$59.07


$48.21


22.5%

Gross profit


$25.81


$18.69


38.1%

Gross margin


43.7%


38.8%


4.9 pp

Operating income


$17.63


$11.47


53.8%

Operating margin


29.9%


23.8%


6.1 pp

Net income attributable to CYIG


$12.91


$8.82


46.3%

Earnings per share


$0.43


$0.30


46.1%

  • Total revenues increased by 22.5% to $59.07 million with growth in sales across all three product categories. Sales of acer truncatum seed oil products were particularly strong, increasing by 76.9% to $15.03 million and accounted for 25.4% of total revenues.
  • Overall gross margin increased by 4.9% to 43.7%, benefitting from increased contribution from the higher margin acer truncatum seed oil products and decreases in raw material, packaging and manufacturing costs.
  • Net income attributable to the Company was $12.91 million, or $0.43 per share, compared to $8.82 million, or $0.30 per share, for the same period of the prior fiscal year.

Revenues

For the nine months ended December 31, 2018, total revenues increased by $10.86 million, or 22.5%, to $59.07 million from $48.21 million for the same period of the prior fiscal year. The increase in total revenues was across the all three product categories with sales for acer truncatum seed oil particularly strong.

Revenues from health care products increased by $2.12 million, or 10.6%, to $22.08 million for the nine months ended December 31, 2018 from $19.97 million for the same period of the prior fiscal year. The increase in sales of the health care products was primarily due to the expansion of our customer base and the increase in online direct sales. 

Revenues from Huoliyuan capsules increased by $2.21 million, or 11.2%, to $21.95 million for the nine months ended December 31, 2018 from $19.75 million for the same period of the prior fiscal year. The increase in sales of Huoliyuan capsules was primarily due to the stabilization of market competition.

Revenues from acer truncatum seed oil products increased by $6.53 million, or 76.9%, to $15.03 million for the nine months ended December 31, 2018 from $8.50 million for the same period of the prior fiscal year. The increase in sales of acer truncatum seed oil was primarily due to the continuing promotions of acer truncatum seed oil at conferences highlighting features and benefits of the product to our distributors and customers. Since July 2015 the Company has produced and sold acer truncatum seed oil extracted from the acer truncatum pods purchased from third party vendors. Approximately 10% of the Company's self-grown acer truncatum trees were harvested for production during the fiscal quarter ended December 31, 2018, and the rest of the self-grown acer truncatum pods will be gradually ready for use in production during the next two to three years depending upon the timing of their harvest.

The sales of health care products, Huoliyuan capsules, and acer truncatum seed oil accounted for 37.4%, 37.2%, and 25.4%, respectively, of total revenues for the nine months ended December 31, 2018, compared to 41.4%, 41.0%, and 17.6%, respectively, for the same period of the prior fiscal year.

The following table summarizes revenues and gross profit by products for the nine months ended December 31, 2018 and 2017, respectively:



For the Nine Months Ended December 31,



2018


2017



Revenues
($M)


Gross Profit
($M)


Gross Margin
(%)


Revenues
($M)


Gross Profit
($M)


Gross Margin
(%)

Health care supplements


22.08


9.80


44.4%


19.97


8.90


44.6%

Drugs (Huoliyuan capsule)

21.95


6.51


29.6%


19.75


6.01


30.4%

Acer truncatum oil


15.03


9.50


63.2%


8.50


3.78


44.5%

Total


59.07


25.81


43.7%


48.21


18.69


38.8%

Cost of Goods Sold

Cost of goods sold comprised primarily the cost of finished goods purchased from Shandong Yongchuntang, raw materials of our self-grown acer truncatum pods and pods that we purchased from third party vendors, and the manufacturing cost of acer truncatum seed oil and Huoliyuan capsules. For the nine months ended December 31, 2018, total cost of goods sold increased by $3.74 million, or 12.7%, to $33.26 million from $29.52 million for the same period of the prior fiscal year.

As a percentage of revenues, total cost of goods sold was 56.3% for the nine months ended December 31, 2018, compared to 61.2% for the same period of the prior fiscal year. The decrease was primarily due to the decreased raw material, packaging and manufacturing costs for acer truncatum seed oil products.

Cost of goods sold for health care products, Huoliyuan capsules, and acer truncatum seed oil products were $12.28 million, $15.44 million and $5.53 million, respectively for the nine months ended December 31, 2018, compared to $11.07 million, $13.74 million, and $4.72 million, respectively, for the same period of the prior fiscal year.

Gross Profit

Gross profit increased by $7.12 million, or 38.1%, to $25.81 million for the nine months ended December 31, 2018, from $18.69 million for the same period of the prior fiscal year. Gross profit for health care products, Huoliyuan capsules, and acer truncatum seed oil were $9.80 million, $6.51 million, and $9.50 million, respectively, for the nine months ended December 31, 2018, compared to $8.90 million, $6.01 million, and $3.78 million, respectively, for the same period of the prior fiscal year.

Overall gross margin was 43.7%, with gross margins for health care products, Huoliyuan capsules, and acer truncatum seed oil being 44.4%, 29.6%, and 63.2%, respectively, for the nine months ended December 31, 2018. Overall gross margin was 38.8%, and gross margins for health care products, Huoliyuan capsules, and acer truncatum seed oil were 44.6%, 30.4%, and 44.5%, respectively, for the same period of the prior fiscal year. The increase in overall gross margin was mainly due to the increased contribution from the higher margin acer truncatum seed oil.

Operating Expenses

Selling expenses consist primarily of sales commissions, advertising and promotion, freight charges, and related compensation. For the nine months ended December 31, 2018, selling expenses increased by $0.39 million, or 10.7%, to $3.98 million from $3.60 million for the same period of the prior fiscal year. The increase in selling expenses was primarily due to the increases in shipping cost and sales commission as a result of increased sales.

General and administrative expenses increased by $0.28 million, or 8.7%, to $3.50 million for the nine months ended December 31, 2018 from $3.22 million for the same period of the prior fiscal year. The increase in general and administrative expenses was primarily due to the increase in depreciation and amortization expenses, and legal and consulting fees.

Research and development expenses increased by $0.28 million, or 69.3%, to $0.69 million for the nine months ended December 31, 2018 from $0.41 million for the same period of the prior fiscal year. The increase in research and development expenses was mainly due to the increased cost of the materials used by the R&D department. As of December 31, 2018, the Company had a staff of 27 in its R&D department.

As a result, total operating expenses increased by $0.95 million, or 13.1%, to $8.18 million for the nine months ended December 31, 2018, from $7.23 million for the same period of the prior fiscal year.

Operating Income

Total operating income increased by $6.17 million, or 53.8%, to $17.63 million for the nine months ended December 31, 2018, from $11.47 million for the same period of the prior fiscal year. The increase in total operating income was mainly a result of increased gross profit, partially offset by increased operating expenses. Operating margin was 29.9% for the nine months ended December 31, 2018, compared to 23.8% for the same period of the prior fiscal year.

Income before Income Taxes

Interest income was $0.11 million for the nine months ended December 31, 2018, compared to $0.09 million for the same period of the prior fiscal year. The Company also booked gain on disposal of acer truncatum bunge plants of $0.57 million for the nine months ended December 31, 2018.

Income before income tax provisions increased by $5.62 million, or 46.3%, to $17.74 million for the nine months ended December 31, 2018, from $12.13 million for the same period of the prior fiscal year.

Net Income

Provision for income tax increased by $1.40 million, or 46.3%, to $4.44 million for the nine months ended December 31, 2018, from $3.03 million for the same period of the prior fiscal year.

Net income increased by $4.21 million, or 46.3%, to $13.31 million for the nine months ended December 31, 2018, from $9.10 million for the same period of the prior fiscal year.

After the deduction of non-controlling interest, net income attributable to the Company was $12.91 million, or $0.43 per basic and diluted share for the nine months ended December 31, 2018, compared to $8.82 million, or $0.30 per basic and diluted share, for the same period of the prior fiscal year.

Liquidity and Capital Resources

As of December 31, 2018, the Company had cash and cash equivalents of $35.96 million, compared to $25.35 million as of March 31, 2018. Inventories was $3.58 million as of December 31, 2018, compared to $2.38 million as of March 31, 2018. The increase in inventories was mainly due to the increase in raw materials. Total working capital was $39.60 million as of December 31, 2018, compared to $28.08 million as of March 31, 2018.

Net cash provided by operating activities was $13.79 million for the nine months ended December 31, 2018, compared to $12.13 million for the same period of the prior fiscal year. Net cash used in investing activities was $0.74 million for the nine months ended December 31, 2018, compared to $4.45 million for the same period of the prior fiscal year. Net cash provided by financing activities was $nil for the nine months ended December 31, 2018 and 2017, respectively. 

About Spring Pharmaceutical Group, Inc.

Based in Jining, Shandong Province and founded in January 1989, Spring Pharmaceutical Group, Inc., through its subsidiaries, engages in the business of (i) distributing health care supplement products manufactured by Shandong Yongchuntang Group Co., Ltd. in the PRC, (ii) developing, manufacturing, and selling Huoliyuan capsules, a prescription medicine, (iii) developing acer truncatum bunge planting bases, and manufacturing and selling acer truncatum bunge seed oil in the PRC. Acer truncatum bunge plants are a species of maple tree. For more information about the Company, please visit http://www.yctgroup.com/.

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulations, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by this cautionary statement and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

At the Company:
Zecheng Shao, Vice President
Phone: +86-156-5377-2006
Email: zc_shao@126.com

Investor Relations:
Tony Tian, CFA
Weitian Group LLC
Phone: +1-732-910-9692
Email: ttian@weitianco.com

SPRING PHARMACEUTICAL GROUP, INC.

(FORMERLY KNOWN AS CHINA YCT INTERNATIONAL GROUP, INC.)

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)




THREE MONTHS ENDED



NINE MONTHS ENDED

DECEMBER 31,

DECEMBER 31,



2018



2017



2018



2017













Sales


$

19,494,574



$

17,211,156



$

59,068,360



$

48,212,805

Cost of Goods Sold (including
$3,922,496 and $3,623,226 from a
related party for the three months ended
December 31, 2018 and 2017,
respectively; including $12,098,816 and
$10,932,869 from a related party for the
nine months ended December 31, 2018
and 2017, respectively)



10,674,733




10,422,916




33,259,278




29,521,454

Gross profit



8,819,841




6,788,240




25,809,082




18,691,351

Operating expenses
















Selling expenses



1,278,446




1,278,544




3,982,927




3,596,983

General and administrative expenses



1,311,969




1,445,469




3,504,013




3,222,132

Research and development expenses



297,089




280,229




688,246




406,640

Total operating expenses



2,887,504




3,004,242




8,175,186




7,225,755

Income from operations



5,932,337




3,783,998




17,633,896




11,465,596

Gain on disposal of acer truncatum
bunge plants



-




-




-




573,092

Interest income



35,141




32,376




110,186




88,678

Income before income tax provision



5,967,478




3,816,374




17,744,082




12,127,366

Income tax provision



1,491,869




954,093




4,436,020




3,031,841

Net income



4,475,609




2,862,281




13,308,062




9,095,525

Less: Net income attributable to
noncontrolling interest



134,268




85,869




399,242




272,866

Net income attributable to the Company



4,341,341




2,776,412




12,908,820




8,822,659

Other comprehensive income (loss):
















Foreign currency translation adjustment



278,156




1,557,010




(9,384,322)




5,121,310

Comprehensive income



4,753,765




4,419,291




3,923,740




14,216,835

Less: Comprehensive income
attributable to noncontrolling interest



142,613




132,578




117,713




425,325

Comprehensive income attributable to
the Company


$

4,611,152



$

4,286,713



$

3,806,027



$

13,791,510

















Earnings per common share
















Basic and Diluted


$

0.15



$

0.09



$

0.43



$

0.30

















Weighted average number of common
shares outstanding
















Basic and Diluted



29,839,168




29,789,168




29,827,532




29,789,168

 

SPRING PHARMACEUTICAL GROUP, INC.

(FORMERLY KNOWN AS CHINA YCT INTERNATIONAL GROUP, INC.)

CONSOLIDATED BALANCE SHEETS

(Unaudited)




DECEMBER 31,



MARCH 31,



2018



2018







Assets












Current assets:






Cash and cash equivalents


$

35,962,549



$

25,353,360

Accounts receivable



180,894




174,558

Inventories



3,579,491




2,383,382

Purchase deposit to related party



1,195,399




1,412,864

Prepaid leases – current portion



858,659




741,583

Total current assets



41,776,992




30,065,747









Prepaid leases



1,107,793




641,349

Development cost of acer truncatum bunge planting, net



45,442,082




48,984,881

Plant, property, and equipment, net



14,492,277




16,793,413

Intangible assets, net



9,939,499




11,862,017

Deferred tax assets



85,620




200,387

Security deposit to related party



1,457,046




1,590,305

Total assets


$

114,301,309



$

110,138,099









Liabilities and Stockholders' Equity
















Current liabilities:








Accounts payable and other accrued expenses


$

107,701



$

372,782

Advance from customers



-




445,829

Taxes payable



2,073,578




1,164,198

Total current liabilities



2,181,279




1,982,809









Stockholders' Equity








Preferred stock, par value $0.001 per share; 5,000,000
shares authorized, zero shares issued and outstanding



-




-

12% Preferred stock, par value $500 per share; 45 shares
authorized, issued and outstanding



22,500




22,500

Common stock, par value $0.001 per share; 100,000,000
shares authorized; 29,839,168 and 29,789,168 shares issued
and outstanding at December 31, 2018 and March 31, 2018,
respectively



29,839




29,789

Additional paid-in capital



4,363,788




4,322,838

Statutory reserve



1,828,504




1,828,504

Retained earnings



107,356,757




94,447,937

Accumulated other comprehensive income (loss)



(4,647,776)




4,455,017

Total stockholders' equity attributable to the Company



108,953,612




105,106,585

Noncontrolling interest



3,166,418




3,048,705

Total stockholders' equity



112,120,030




108,155,290

Total liabilities and stockholders' equity


$

114,301,309



$

110,138,099

 

SPRING PHARMACEUTICAL GROUP, INC.

(FORMERLY KNOWN AS CHINA YCT INTERNATIONAL GROUP, INC.)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)




NINE MONTHS ENDED

DECEMBER 31,



2018



2017

Cash Flows From Operating Activities:






Net income


$

13,308,062



$

9,095,525

Adjustments to reconcile net income to net cash provided by
operating activities:








Amortization of development cost of accer tructum bunge planting



75,435




-

Depreciation and amortization of plant, property and equipment



1,007,443




951,711

Amortization of intangible assets



951,318




949,886

Amortization of prepaid leases



659,787




654,324

Stock-based compensation expenses



41,000




-

Deferred taxes



100,378




268,475

Gain on disposal of acer truncatum bunge plants



-




(573,092)

Changes in operating assets and liabilities:








Purchase deposit to vendors



-




669,250

Inventory



(1,430,058)




2,286,222

Accounts receivable



(21,477)




962,842

Cash received from cancellation of lease



-




57,137

Prepaid expenses



-




(175,771)

Prepaid leases



(1,376,345)




-

Taxes payable



1,031,631




(1,034,267)

Purchase deposit and accounts payable to related party, net



101,505




(1,996,995)

Accounts payable and other accrued expenses



(239,579)




17,174

Advance from customers



(418,489)




-

Net cash provided by operating activities



13,790,611




12,132,421









Cash Flows From Investing Activities:








Acquisition of property, plant and equipment



(91,582)




(2,125,638)

Proceeds from disposal of acer truncatum bunge plants



-




2,129,638

Development cost of acer truncatum bunge planting



(651,092)




(4,457,916)

Net cash used in investing activities



(742,674)




(4,453,916)









Effect of exchange rate changes on cash and cash equivalents



(2,438,748)




781,409

Net increase in cash and cash equivalents



10,609,189




8,459,914

Cash and cash equivalents at beginning of period



25,353,360




10,308,622

Cash and cash equivalents at end of period


$

35,962,549



$

18,768,536









Supplemental disclosures of cash flow information:








Cash paid during the periods for:








Interest


$

-



$

-

Income taxes


$

3,342,017



$

3,495,744

 

Cision View original content:http://www.prnewswire.com/news-releases/spring-pharmaceutical-group-inc-reports-financial-results-for-the-three-and-nine-months-ended-december-31-2018-300795903.html

Source: Spring Pharmaceutical Group, Inc.

Related stocks: OTC:CYIG

from common-pcom:html:key:en_segment_includes_releases_right_column_video_module_shtml

Featured Video

Banking/Financial Service Recent Releases

Health Care/Hospital Recent Releases

Medical/Pharmaceuticals Recent Releases

Pharmaceuticals Recent Releases

from common-pcom:html:key:en_segment_includes_overall_segment_footer_shtml
Advanced Search
Search
  
  1. Products & Services
  2. News Releases
  3. Knowledge Center
  4. Journalists & Media
  5. Multimedia Theater
  6. Contact Us